AID-JUNCT study: GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery

Innovative approaches to combination therapy in type 1 Diabetes

Glycemic control in type 1 diabetes (T1D) remains a challenge, with ~32% of adults in Switzerland achieving an A1c target of <7%. The dual glucagon-like peptide-1 receptor agonists (GLP-1RAs) and glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RAs has emerged as promising therapy in T1D. Retrospective studies have shown people with T1D can significantly improve glycemic control with a reduction in insulin dose and body weight when long-acting GLP-1RAs or GIP/GLP-1RAs are added to insulin therapy.

This study will assess glycemic control in people with T1D on a stable dose of long-acting GIP/GLP-1RA (Tirzepatide) as an adjuvant therapy to automated insulin delivery (AID). We are conducting a prospective, parallel, open-label, randomized clinical trial to test the hypothesis that available AID systems combined with GIP/GLP-1RA will lead to safe and more efficacious glycemic control than Standard of Care (SoC) during the assessment period. The outcome of this study will provide unique data about the safety and efficacy of using GIP/GLP1-RA as adjuvant therapy to AID systems. 

Sponsor: Prof. José García-Tirado, PhD – University of Berne
Principal investigator: PD Dr. med. Thomas Züger, Chief Physician – Kantonsspital Olten
Funding: Internal funds